Accueil / Communiqués / Global Biomarker Technologies, Markets & Companies, 2019-2028: Proteomics, Metabolomics, Molecular Diagnostics, Drug Discovery, Clinical Trials, and Bioinformatics –

Global Biomarker Technologies, Markets & Companies, 2019-2028: Proteomics, Metabolomics, Molecular Diagnostics, Drug Discovery, Clinical Trials, and Bioinformatics –

Monday, February 4th 2019 at 11:22am UTC

DUBLIN–(BUSINESS WIRE)– The « Biomarkers
– Technologies, Markets & Companies »
report from Jain
PharmaBiotech has been added to’s

Biomarker markets are estimated from 2018 to 2028 according to share of
markets for various technologies and applications: proteomics,
metabolomics, molecular diagnostics, drug discovery, clinical trials,
and bioinformatics.

Market values are further split according to therapeutic applications
and major geographical areas. Unfulfilled needs in biomarkers are
identified as well as the drivers for biomarker markets. Challenges
facing the biomarker industry and strategies for developing biomarker
markets are discussed.

A large number of companies with varying technical backgrounds are
involved in biomarkers and 301 of these are profiled in part 2 of the
report with classification into various categories.These also include
major pharmaceutical companies. There is tabulation of 471
collaborations between companies and additional academic collaborations
are mentioned in the individual profiles of companies. The report is
supplemented by 1000 references, 81 tables and 23 figures


This report follows the broad definition of a biomarker as a
characteristic that can be objectively measured and evaluated as an
indicator of normal biological or pathogenic processes as well as
pharmacological responses to a therapeutic intervention.

Tests based on biomarkers have been around for more than half a century,
but interest in their application for diagnostics and drug discovery as
well as development has increased remarkably since the beginning of the
21st century.

This report describes different types of biomarkers and their discovery
using various -omics technologies such as proteomics and metabolomics.
Molecular diagnostics technologies are used for the discovery of
biomarkers and new tests are also based on biomarker.

Currently the most important applications of biomarkers are in drug
discovery and development. The role of biomarkers in various therapeutic
areas particularly cancer, cardiovascular diseases and disorders of the
central nervous system, is described. Biomarkers are useful not only for
diagnosis of some of these diseases but also for understanding the
pathomechanism as well as a basis for development of therapeutics.

Biomarkers will facilitate the combination of therapeutics with
diagnostics and will thus play an important role in the development of
personalized medicine. Biomarkers play a role in use of
pharmacogenetics, pharmacogenomics and pharmacoproteomics for
development of personalized medicine.

Many of the regulatory issues concerning biomarkers are related to
genomics, proteomics, molecular diagnostics and
pharmacogenomics/pharmacogenetics. Validation of biomarkers and their
role in clinical trials is discussed.

The report covers the following areas:

  • Technologies for Discovery of Biomarkers
  • Biomarkers and Molecular Diagnostics
  • Biomarkers for Drug Discovery and Development
  • Role of Biomarkers in Healthcare
  • Biomarkers in Metabolic Disorders
  • Biomarkers in Immune Disorders
  • Biomarkers of Musculoskeletal Disorders
  • Biomarkers of Infectious Diseases
  • Biomarkers of Genetic Disorders
  • Biomarkers of Aging
  • Nutritional Biomarkers
  • Biomarkers in Cancer
  • Biomarkers of Disorders of the Nervous System
  • Biomarkers of Cardiovascular Disorders
  • Biomarkers of Pulmonary Diseases
  • Biomarkers in Gynecology and Obstetrics
  • Biomarkers and Personalized Medicine
  • Regulatory issues
  • Markets for Biomarkers
  • Companies

For more information about this report visit

Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Biomarkers

Source: Research and Markets

Voir aussi

Maverick Therapeutics to Unveil Pre-Clinical Data on Novel COBRATM Platform at American Association for Cancer Research 2019 Annual Meeting

Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent …